MAPK7 and benign prostatic hyperplasia: Importantly, nuclear ERK5 immuno-reactivity in metastatic PCa was significantly stronger than that observed in BPH and primary PCa (P=0.013 and P<0.0001, respectively, Mann–Whitney test; Figures 4A–D, G and H).